BIIBBiogen Inc.
215.65USD-2.67%Mkt Cap: 32.74B $P/E: 39.35

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple…

Key Statistics

Company
Market Cap32.74B $
Enterprise Value38.74B $
Revenue (TTM)10.03B $
Gross Profit7.49B $
Net Income (TTM)1.29B $
Revenue/Share68.19 USD
Last Price215.65 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees7.5K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISINUS09062X1037
Valuation
P/E (Trailing)39.35
P/E (Forward)12.96
PEG1.57
EV/EBITDA11.53
EV/Revenue3.86
P/S3.16
P/B1.68
EPS (TTM)5.44
EPS (Forward)16.54
52W Range
131.5293% of range222.15
52W High222.15 USD
52W Low131.52 USD
Profitability
Gross Margin75.69%
Oper. Margin25.06%
EBITDA Margin33.50%
Profit Margin13.07%
ROE7.08%
ROA4.39%
Growth
Revenue Growth3.40%
Earnings Growth-84.80%
Cash Flow & Leverage
Operating CF2.20B $
CapEx (TTM)235.40M $
FCF Margin12.63%
FCF Yield3.87%
Net Debt7.07B $
Net Debt/EBITDA2.10
Balance Sheet
Debt/Equity0.36
Current Ratio1.86
Quick Ratio0.94
Book Value/Sh127.61 USD
Cash/Share8.697 USD
Dividends
Fwd Div Rate
Trail. Div Rate0.0000 USD
Div. Yield
5Y Avg Yield
Payout Ratio0.00%
Ex-Div Date
Pay Date
Splits
Last Split3:1
Split DateJan 18, 2001
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)235.57 USD
Upside (mean)+9.2%
Target Range165.00 USD300.00 USD
$165.00+9.2% to mean$300.00
# Analysts31
Ownership
Shares Out.147.75M
Float147.22M
Insiders0.19%
Institutions99.50%
Short Interest
Short Ratio3.8d
Short % Float4.11%
Short % Out.3.69%
Shares Short5.45M
Short (prev mo.)5.72M
Technical
SMA 50204.82 (+5.3%)
SMA 200187.66 (+14.9%)
Beta0.16
S&P 52W Chg18.16%
Avg Vol (30d)1.16M
Avg Vol (10d)769.37K
Technical Indicators
RSI (14)65.0
MACD2.7655
MACD Signal1.7051
MACD Hist.+1.0604
BB Upper216.65 USD
BB Middle206.43 USD
BB Lower196.21 USD
BB Width9.90%
ATR (14)6.888 USD
Vol Ratio (20d)0.98x